Source: ALL

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 100128998
Gene Symbol: C20orf181
C20orf181
CUI: C0039585
Disease: Androgen-Insensitivity Syndrome
Androgen-Insensitivity Syndrome 		0.040 Biomarker BEFREE Intravenous recombinant tissue plasminogen activator remains the most frequently applied reperfusion therapy in AIS patients presenting within 4.5 h of onset in a tertiary stroke centre. 30317687

2019
Entrez Id: 100128998
Gene Symbol: C20orf181
C20orf181
CUI: C0039585
Disease: Androgen-Insensitivity Syndrome
Androgen-Insensitivity Syndrome 		0.040 Biomarker BEFREE Therefore, low-dose tPA is highly recommended in AIS patients. 29111341

2018
Entrez Id: 100128998
Gene Symbol: C20orf181
C20orf181
CUI: C0039585
Disease: Androgen-Insensitivity Syndrome
Androgen-Insensitivity Syndrome 		0.040 Biomarker BEFREE We aimed to evaluate current edaravone treatment practices and the efficacy and safety of edaravone used with recombinant tissue plasminogen activator (tPA) in AIS patients within 4.5 hours of onset. 27887792

2017
Entrez Id: 100128998
Gene Symbol: C20orf181
C20orf181
CUI: C0039585
Disease: Androgen-Insensitivity Syndrome
Androgen-Insensitivity Syndrome 		0.040 GeneticVariation BEFREE To explore rural-urban differences and trends in tissue plasminogen activator (tPA) utilization among acute ischemic stroke (AIS) patients and examine the association between primary stroke center (PSC) growth and geographic disparity in tPA use. 28053009

2017